Ethan Rowin

Lahey Hospital and Medical Center is currently looking to hire a structural fellow for the 2026-2027 academic year. Join a collegial and busy team with large volumes that is always coming up with creative solutions! If you would like to apply, please message me.

Low Incidence of Atrial Fibrillation in Patients with Obstructive HCM Treated with Aficamten: An Analysis from the REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM Trials #OpenAccess @EthanRowin @LaheyHospital heartrhythmjournal.com/article/S1547-…

In obstructive #HCM, #pVO2, #NYHA, and #KCCQ don’t always align! Weak correlations and frequent patient-level discordance raise considerations for optimal metric selection in clinical practice and clinical trial design. 🔗kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2…

@AmroAglanMD Awesome! Well deserved. Congratulations

Honored to join @JAHA_AHA Early Career Editorial Board starting January 2026. Grateful for the opportunity to learn the editorial process and contribute to high-quality cardiovascular and arrhythmia research. #CardioTwitter #EPeeps

Low Incidence of Atrial Fibrillation in Patients with Obstructive HCM Treated with Aficamten: An Analysis from the REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM Trials #OpenAccess @EthanRowin @LaheyHospital heartrhythmjournal.com/article/S1547-…

We presented long-term data from #FOREST #HCM on the incidence and impact of atrial fibrillation in patients treated with aficamten in the Cardiomyopathy LBCT session Led by @EthanRowin #ESC2025 #CardioTwitter

Extended Ambulatory ECG Monitoring Enhances Identification of Higher-Risk Ventricular Tachyarrhythmias in Patients with Hypertrophic Cardiomyopathy #OpenAccess @EthanRowin @MartinMaronMD heartrhythmjournal.com/article/S1547-…

Amazing session on #HCM and arrhythmias — from the newer high-risk makers to challenges of VT ablation, role of PFA, and updated exercise guidelines. #EPeeps #HRS2025 #2025pacesetter @EthanRowin

@MasriAhmadMD Agree re trade offs and also surprised with a 6month duration btwn echos for pts with EF55-60%, especially since in MAVA-LTE ~6% of patients had either EF<50 or acute HF btwn wks 48 and 156. So potential for more adverse outcomes with this change. Will see with time.

New mavacamten FDA label update Most relevant parts: 1) Initiation strategy remains the same 2) Maintenance phase echo requirement dropped to once every 6 months instead of once every 3 months This will help with patient and staff burden during the maintenance phase. I would have considered LVEF>60% rather than 55% given the variability and the trade-offs. We plan to continue to study the real-world use of mavacamten and safety outcomes with these changes. Such changes will limit the clinicians' ability to get more frequent echos if concerned about a particular patient since most payers will follow the REMS and decline additional echos. Initiation phase remains rigid without flexibility in echo scheduling, and the downtitration requirements did not change either. Overall really positive changes that our patients will like but there will be trade offs. #CardioTwitter

How have HCM mortality rates changed before and after COVID ❓ 1⃣ Prior to COVID, mortality rates declined by ~ half📉 2⃣ After COVID, mortality rates increased by ~30%, partially undoing some of the prior reductions in HCM mortality.📈 Open access📜: ahajournals.org/doi/full/10.11…

Really valuable and novel data presented by Dr. @EthanRowin — Does LV apical aneurysm size matter for SCD risk in #HCM? 🏥 Multicenter data says yes! #ACC25 #CardioTwitter

“Excited to share our latest editorial published in @CircAHA - Our study highlights T1 mapping as a novel marker for heart failure progression in hypertrophic cardiomyopathy (HCM). @EthanRowin @JAHA_AHA @AHAScience

Mavacamten in #nonobstructive #HCM design and baseline characteristics paper is out (ODYSSEY trial) ! Biggest unmet need in HCM is nonobstructive HCM. We look forward to the results. Impressive baseline characteristics with significant burden of disease Sample size caught my eye. The study planned to enroll 420 patients, yet the paper shows 580 patients were randomized. The paper does not provide rationale (if I missed it please point it out). This makes ODYSSEY the largest study conducted in #HCM Other interesting aspects: unclear how titration is being approached, and this is the first time we see a global study of mavacamten with 1 mg being used. Results expected this year jacc.org/doi/epdf/10.10…

Disopyramide appears safe and effective in treating symptomatic outflow obstruction in HCM over extended durations of time (≥5 years). #AHAJournals @danmassera @nyulangone @EthanRowin @LaheyHospital ahajrnls.org/4hC5AnC

Disopyramide for long-term treatment of obstructive #hcm? Check out our work looking at patients treated for ≥5 years at @nyulangone @LaheyHospital with 67% still on drug after ~7 years @EthanRowin @MartinMaronMD ahajournals.org/doi/full/10.11…

@jeffreygeske @hcmsociety Had a great time talking with @jeffreygeske about management of apical aneurysms in HCM

#cardiotwitter: How do you approach apical aneurysms in hypertrophic #cardiomyopathy? Excited to contribute to the latest @hcmsociety "In the Thick of It" podcast with @EthanRowin #cvHCM pod.link/1694758840/epi…

@MasriAhmadMD Congrats! Impressive results. The AFib data is remarkably low and very reassuring. Do you have publicly available info on timing of the few EF drops?

While these SRT eligibility cut offs are arbitrary - patients do ask the question: what are the chances that this medication can work and allow me to avoid surgery/procedure? These data can help mange such a conversation once aficamten becomes commercially available

We presented new data from #FOREST #HCM which is an ongoing 5 year long term extension trial of aficamten. This analysis is restricted to 280 pts with #oHCM Primary endpoint at week 12 Titration period in the first 6 weeks given its half life Follow along #CardioTwitter

@RickNishimura and Dr. Barry Maron at #HCMSummit8. Great to hear from many experts on HCM. @HCMSummit @SteveOmmen @MartinMaronMD